|Application ||WB, E|
|Calculated MW||136001 Da|
|Antigen Region||835-864 aa|
|Other Names||Probable tumor suppressor protein MN1, MN1|
|Target/Specificity||This MN1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 835-864 amino acids from the Central region of human MN1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||MN1 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Transcriptional activator which specifically regulates expression of TBX22 in the posterior region of the developing palate. Required during later stages of palate development for growth and medial fusion of the palatal shelves. Promotes maturation and normal function of calvarial osteoblasts, including expression of the osteoclastogenic cytokine TNFSF11/RANKL. Necessary for normal development of the membranous bones of the skull (By similarity). May play a role in tumor suppression (Probable).|
|Tissue Location||Ubiquitously expressed. Highest levels in skeletal muscle|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Meningioma 1 (MN1) contains two sets of CAG repeats. It is disrupted by a balanced translocation (4;22) in a meningioma, and its inactivation may contribute to meningioma 32 pathogenesis.
Liu, T., et al. Leukemia 24(3):601-612(2010)
Kandilci, A., et al. Blood 114(8):1596-1606(2009)
Trynka, G., et al. Gut 58(8):1078-1083(2009)
Langer, C., et al. J. Clin. Oncol. 27(19):3198-3204(2009)
Schroeder, T., et al. Leuk. Lymphoma 50(6):1043-1046(2009)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.